- CytomX Therapeutics Inc's CTMX Phase 2 study of praluzatamab ravtansine in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-non-amplified breast cancer (Arm A) met its primary efficacy endpoint of confirmed objective response rate (ORR) of more than 10%.
- As of the data cutoff on May 13, 47 patients unselected for CD166 expression with advanced HR+/HER2-non-amplified breast cancer were evaluable for the primary efficacy endpoint.
- The ORR was 15% in 47 evaluable patients. The clinical benefit rate at 24 weeks was 40%, and the median progression-free survival was 2.6 months.
- All patients in Arm A were treated at the initial Phase 2 starting dose of 7 mg/kg administered every three weeks. Arm B did not pass the protocol-defined futility boundary (ORR was less than 10%) in patients with advanced triple-negative breast cancer (TNBC).
- Enrollment into Arms B and C will be discontinued.
- The safety profile of praluzatamab ravtansine in Arm A was generally consistent with toxicities observed in Phase 1. 30% of patients discontinued treatment for an adverse event.
- Biomarker analysis is ongoing. CytomX intends to submit data from this study for presentation at a medical conference in 2H of 2022.
- Price Action: CTMX shares are down 18.8% at $1.60 during the premarket session on the last check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.